Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Clinical Trial to Determine the Effect of Famciclovir on Epstein-Barr Virus Activity as Measured by EBV Shedding in Saliva of Patients With Multiple Sclerosis.

NCT05283551 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT05283551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Clinical Trial to Determine the Effect of Famciclovir on Epstein-Barr Virus Activity as Measured by EBV Shedding in Saliva of Patients With Multiple Sclerosis.
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Unknown status
Start date
November 25, 2020
Completion date
November 25, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis